Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

J Ole Eriksen; M-B Jensen; A-V Laenkholm; T Kibøll; B Bruun Rasmussen; A S Knoop; S Ferree; T Haffner; W Buckingham; C Schaper; B Ejlertsen

doi:10.1158/1538-7445.SABCS15-P2-08-10

Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

J Ole Eriksen, M-B Jensen, A-V Laenkholm, T Kibøll, B Bruun Rasmussen, A S Knoop, S Ferree, T Haffner, W Buckingham, C Schaper, B Ejlertsen

Department of Clinical Medicine

Original language	English
Article number	P2-08-10
Journal	Cancer Research
Volume	76
Issue number	4 Supplement
Number of pages	1
ISSN	0008-5472
DOIs	https://doi.org/10.1158/1538-7445.SABCS15-P2-08-10
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1538-7445.SABCS15-P2-08-10

Cite this

Eriksen, J. O., Jensen, M-B., Laenkholm, A-V., Kibøll, T., Rasmussen, B. B., Knoop, A. S., Ferree, S., Haffner, T., Buckingham, W., Schaper, C., & Ejlertsen, B. (2016). Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). Cancer Research, 76(4 Supplement), [P2-08-10]. https://doi.org/10.1158/1538-7445.SABCS15-P2-08-10

Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). / Eriksen, J Ole; Jensen, M-B; Laenkholm, A-V et al.

In: Cancer Research, Vol. 76, No. 4 Supplement, P2-08-10, 2016.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Eriksen, JO, Jensen, M-B, Laenkholm, A-V, Kibøll, T, Rasmussen, BB, Knoop, AS, Ferree, S, Haffner, T, Buckingham, W, Schaper, C & Ejlertsen, B 2016, 'Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)', Cancer Research, vol. 76, no. 4 Supplement, P2-08-10. https://doi.org/10.1158/1538-7445.SABCS15-P2-08-10

Eriksen JO, Jensen M-B, Laenkholm A-V, Kibøll T, Rasmussen BB, Knoop AS et al. Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). Cancer Research. 2016;76(4 Supplement):P2-08-10. doi: 10.1158/1538-7445.SABCS15-P2-08-10

Eriksen, J Ole ; Jensen, M-B ; Laenkholm, A-V et al. / Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). In: Cancer Research. 2016 ; Vol. 76, No. 4 Supplement.

@article{82310531414842db9aded78e2aba59ae,

title = "Validation of prediction of local recurrence (LR) by Prosigna{\textregistered} (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)",

author = "Eriksen, {J Ole} and M-B Jensen and A-V Laenkholm and T Kib{\o}ll and Rasmussen, {B Bruun} and Knoop, {A S} and S Ferree and T Haffner and W Buckingham and C Schaper and B Ejlertsen",

year = "2016",

doi = "10.1158/1538-7445.SABCS15-P2-08-10",

language = "English",

volume = "76",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "4 Supplement",

}

TY - ABST

T1 - Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

AU - Eriksen, J Ole

AU - Jensen, M-B

AU - Laenkholm, A-V

AU - Kibøll, T

AU - Rasmussen, B Bruun

AU - Knoop, A S

AU - Ferree, S

AU - Haffner, T

AU - Buckingham, W

AU - Schaper, C

AU - Ejlertsen, B

PY - 2016

Y1 - 2016

U2 - 10.1158/1538-7445.SABCS15-P2-08-10

DO - 10.1158/1538-7445.SABCS15-P2-08-10

M3 - Conference abstract in journal

SN - 0008-5472

VL - 76

JO - Cancer Research

JF - Cancer Research

IS - 4 Supplement

M1 - P2-08-10

ER -